GT Biopharma (GTBP) Financials

$6.18

$0.20 (3.34%)

As on 10-Sep-2026 16:00EDT

Market cap

$11 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

0

P/B Ratio

3.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	16.34	12.42	14.36	13.58	21.26	57.52
Operating Profit (EBIT)	-16.34	-12.42	-14.36	-13.58	-21.26	-57.52
Other Income	--	--	--	--	--	--
Profit before Tax	-22.08	-28.35	-13.16	-7.60	-20.88	-58.01
Provision for Tax	--	--	--	-0.01	-0.38	0.68
Profit after Tax (Net Income)	-22.08	-28.35	-13.16	-7.60	-20.88	-58.01
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	-58.01

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	3.57	5.79	-1.67	7.48	11.73	21.91
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	--	--	0.06	8.22
Current Liabilities	2.22	2.32	5.90	6.63	4.94	10.26
Total Liabilities	8.01	8.11	4.23	14.11	16.74	32.17

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	--	--	--	0.05	0.17	--
Current Assets	5.79	8.11	4.23	14.06	16.56	32.17
Total Assets	11.58	8.11	4.23	14.11	16.74	32.17
Total Debt*	--	--	--	0.06	0.17	0.03
Net Current Assets	--	5.79	-1.67	7.42	11.62	21.91

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-12.91	-12.90	-8.85	-15.22	-15.61
Cash Flow from Investing Activities	--	--	12.89	-2.01	12.15	-23.04
Cash from Financing Activities	--	15.78	2.98	6.27	-0.22	42.32
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-2.28	-5.14	-6.94	-5.50	-17.65	-6.71
Cash EPS ($)	--	-5.14	-6.94	-5.50	-17.65	-6.71
Adjusted Book Value ($)	--	1.05	--	5.41	9.92	2.53
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.34	-6.80	-6.41	-12.86	-1.80
Free Cash Flow per Share ($)	--	-2.34	-6.80	-6.41	-12.86	-1.80

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-1,377.41	-448.91	-78.15	-123.40	-610.31
ROE (%)	-472.06	-1,377.41	-453.39	-79.09	-124.15	1,577.73
ROA (%)	-210.24	-459.62	-143.53	-49.26	-85.41	-306.70
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	--	--	-262.33	82.01	63.28	-360.41
Net Profit Growth (%)	42.09	-115.42	-73.25	63.62	64.00	-105.02
EPS Growth (%)	84.51	0.26	-0.26	0.69	-1.63	-0.24
Book Value Growth (%)	-94.71	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	0.00	-0.15	-0.44	-0.05	-0.05	-0.45
Price / Book Value	3.62	0.75	-3.46	0.05	0.09	1.20
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.09	0.09	-0.14	-2.27	0.73	0.10
Close Price ($)	12.24	19.63	76.25	191.25	664.28	2,287.50
High Price ($)	93.25	96.25	266.50	825.00	2,805.00	14,799.83
Low Price ($)	6.53	13.50	43.00	134.78	656.70	2,220.00
Market Cap ($ Cr)	10.87	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	0.01	0.01	0.00
Short term debt to equity ratio	--	--	--	0.01	0.01	0.00
Current Ratio	2.61	3.50	0.72	2.12	3.35	3.14
Quick Ratio	2.61	--	--	--	--	--
Interest Coverage	-85.94	--	--	-35.67	-5,277.75	-160.16

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.